Publications

Glepaglutide

Naimi, R.M., et al
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.
Article, EBioMedicine 46 (2019) 444–451, 2019.

Naimi, R.M., et al
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
Article, The Lancet Gastroenterology & Hepatology, 2019

Naimi, R.M., Hvistendahl, M., Groenbaek, H., Vilstrup, H., Moeller, H.J., and Jeppesen, P.B.
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analog, on activation of liver macrophages and gut integrity in patients with short bowel syndrome.
Poster, Digestive Disease Week, San Diego, 2019

Hvistendahl, M., Naimi, R.M., Hansen, S.H., Kissow, H., Pedersen, J., Dragsted, L.O., and Jeppesen, P.B.
Glepaglutide, a novel long-acting glucagon-like peptide-2 analog, ameliorates distrubances in gut-liver axis by triggering farnesoid X receptor signaling pathways inpatients with short bowel syndrome.
Poster, ASPEN Nutrition Science & Practice Conference, Phoenix, 2019

Naimi, R.M., Hvistendahl, M., Holst, J.J., Hartmann, B., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a long-acting glucagon-like peptide-2 analog, alters postprandial intestinal hormone levels but not glucose homeostasis in patients with short bowel syndrome.
Poster, 40th ESPEN Conference, Madrid, 2018

Hvistendahl, M., Naimi, R.M., Nerup, N.A., Ambrus, R.B., Ring, L.L., Achiam, M.P., Svendsen, L.B., Hansen, M.B., and Jeppesen, P.B.
Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on hepatic function as measured by transient elastography and indocyanine green clearance in patients with short bowel syndrome.
Poster, 40th ESPEN Conference, Madrid, 2018.

Naimi, R.M., Hvistendahl, M., Poulsen, S.S., Kissow, H., Andreasen, R.H., Hansen, M.B., and Jeppesen, P.B.
Effects of short-term treatment with glepaglutide, a novel long-acting glucagon-like peptide-2 analog, on intestinal morphology and citrulline in patients with short bowel syndrome.
Presentation (Abstract), Digestive Disease Week, Washington, D.C., 2018

Hvistendahl, M., Naimi, R.M., Enevoldsen, L.H., Madsen, J.L., Fuglsang, S., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a glucagon-like peptide-2 analog, ameliorates accelerated gastrointestinal transit time in patients with short bowel syndrome.
Poster, Digestive Disease Week, Washington, D.C., 2018

Hvistendahl, M., Naimi, R.M., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a novel long-acting glucagon-like peptide-2 analog, improves intestinal absorption of macronutrients, body weight and lean body mass in patients with short bowel syndrome.
Presentation (Abstract), Digestive Disease Week, Washington, D.C., 2018

Naimi, R.M., Hvistendahl, M., Hansen, M.B., and Jeppesen, P.B.
Dose-dependent effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on fecal output in patients with short bowel syndrome
Presentation (Abstract), ASPEN Nutrition Science & Practice Conference, Las Vegas, 2018

Pre-clinical

Skarbaliene, J., Thorkildsen, C., Petersen, Y.M., Berner-Hansen, M., Russell, W.S.
Therapeutic potential of GLP-2 receptor agonist glepaglutide in a rat model of recurrent indomethacin-induced small intestinal inflammation
Poster, UEG Week, Austria, Vienna, 2018

Glerup, P., Sonne, K., Russell, W., Walton, C., Chesher, C.
Intestinotrophic effects of glepaglutide following chronic exposure in rats and dogs
Poster, UEG Week, Austria, Vienna, 2018